Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 80,500 |
5 mg | 在庫あり | ¥ 223,000 |
10 mg | 在庫あり | ¥ 275,500 |
25 mg | 在庫あり | ¥ 365,000 |
50 mg | 在庫あり | ¥ 454,500 |
100 mg | 在庫あり | ¥ 574,000 |
説明 | DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model. |
In vitro | DN-1289 (Compound 14) (0.1, 0.3, and 1 μM; 0-20 h) can block the neurite degeneration induced by nerve growth factor (NGF) withdrawal in dorsal root ganglion (DRG) neurons[1]. DN-1289 (0.1, 0.3, and 1 μM; 0-20 h) inhibits the activation of caspases, apoptotic protease, in NGF withdrawal-induced apoptosis in DRG neurons[1]. |
In vivo | DN-1289 (Compound 14) demonstrates good tolerance in a mouse model at doses of 100 mg/kg and 150 mg/kg administered via intraperitoneal injection once daily for 10-15 days[1]. DN-1289 (150 mg/kg; oral administration; twice daily for 10 days) inhibits c-Jun phosphorylation in the acute optic nerve crush (ONC) injury model[1]. |
分子量 | 441.38 |
分子式 | C18H19F4N7O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (124.61 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DN-1289 DNA Damage/DNA Repair DNA Alkylation Inhibitor inhibitor inhibit